Evidence map›Paper›PMID 40660290›Full record

ArticleBMC biology2025

BertADP: a fine-tuned protein language model for anti-diabetic peptide prediction.

Xueqin Xie, Changchun Wu, Yixuan Qi, Shanghua Liu, Jian Huang, Hao Lyu, Fuying Dao, Hao Lin

Abstract read
In one paragraph

Article in BMC biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xueqin Xie *The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Changchun Wu *The Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Yixuan QiThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Shanghua LiuThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Jian HuangThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China.
Hao LyuThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China. hao.lyu@uestc.edu.cn.
Fuying DaoSchool of Biological Sciences, Nanyang Technological University, Singapore, 639798, Singapore. fuying.dao@ntu.sg.edu.
Hao LinThe Clinical Hospital of Chengdu Brain Science Institute, School of Life Science and Technology, University of Electronic Science and Technology of China, Chengdu, 610054, China. hlin@uestc.edu.cn.

Funding

China Postdoctoral Science Foundation 2023TQ0047Major Project of the Fundamental Research Funds for the Central Universities ZYGX2024Z011National Natural Science Foundation of China 62402089National Natural Science Foundation of China 82130112Sichuan Science and Technology Program 2025ZNSFSC1465
6 · The paper itself

Abstract

backgroundDiabetes is a global metabolic disease that urgently calls for the development of new and effective therapeutic agents. Anti-diabetic peptides (ADPs) have emerged as a research hotspot due to their therapeutic potential and natural safety, representing a promising class of functional peptides for diabetic management. However, conventional computational approaches for ADPs prediction mainly rely on manually extracted sequence features. These methods often lack generalizability and perform poorly on short peptides, thereby hindering effective ADPs discovery.

resultsIn this study, we introduce a fine-tuning strategy of large-scale pre-trained protein language models (PLMs) for ADPs prediction, enabling automated extraction of discriminative semantic representations. We established the most comprehensive ADPs dataset to date, comprising 899 rigorously curated non-redundant ADPs and 67 newly collected potential candidates. Based on three model construction strategies, we developed 11 candidate models. Among them, BertADP (a fine-tuned ProtBert model) demonstrated superior performance in the independent test set, outperforming existing ADPs prediction tools with an overall accuracy of 0.955, sensitivity of 1.000, and specificity of 0.910. Notably, BertADP exhibited remarkable sequence length adaptability, maintaining stable performance across both standard and short peptide sequences.

conclusionsBertADP represents the first PLMs-based intelligent prediction tool for ADPs, whose exceptional identification capability will significantly accelerate anti-diabetic drug development and facilitate personalized therapeutic strategies, thereby enhancing precision diabetes management. Furthermore, the proposed approach provides a generalizable framework that can be extended to other bioactive peptide discovery studies, offering an innovative solution for bioactive peptide mining.

Indexed as

Computational BiologyHypoglycemic AgentsPeptidesHumansHypoglycemic AgentsPeptidesAnti-diabetic peptidesBioactive peptide predictionDeep learningFine-tuningProtein language models

Identifiers

PMID40660290
PMCPMC12261731

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.